Company / Accounts Receivable
RxSight, Inc. Accounts Receivable History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$23.4M
FY2025
5-year range
$4.9M / $30.1M
FY2021-FY2025
Trend
-22.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $20M to $23M over the past 2 years.
Based on SEC 10-K filings.
$23M in FY2025 with a 3-year CAGR of +28.8%.
Improved from $20M to $23M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +28.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +28.8%, indicating consistent growth.
- In FY2025, accounts receivable decreased 22.2% year-over-year.
- Peak accounts receivable was recorded in FY2024.
- Lowest accounts receivable in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 3.59 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $23.4M | -22.2% |
| FY2024 | $30.1M | +48.2% |
| FY2023 | $20.3M | +85.1% |
| FY2022 | $11.0M | +125.3% |
| FY2021 | $4.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026